Aarti Pharma

Who are the top shareholders of the Aarti Pharma?

The top shareholders of Aarti Pharma include promoter Rashesh Chandrakant Gogri with 4.23%, Life Insurance Corporation of India at 6.06%, 109 Foreign Institutional Investors holding 7.36%, mutual funds at 0.78%, and individual investors collectively owning 34.1%.

The top shareholders of Aarti Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Rashesh Chandrakant Gogri, owning 4.23%. Among public shareholders, the Life Insurance Corporation of India is the largest, holding 6.06%. Additionally, institutional investors are represented by 109 Foreign Institutional Investors (FIIs) with a combined holding of 7.36%, and mutual funds hold 0.78% through seven schemes. Individual investors collectively hold 34.1% of the shares.

how big is Aarti Pharma?

As of Jun 06, Aarti Pharmalabs Ltd has a market capitalization of 8,323.00 Cr and reported net sales of 2,115.08 Cr and net profit of 272.40 Cr over the latest four quarters.

Market Cap: <BR>As of Jun 06, Aarti Pharmalabs Ltd has a market capitalization of 8,323.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, Aarti Pharmalabs Ltd reported a sum of Net Sales of 2,115.08 Cr and a sum of Net Profit of 272.40 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,757.04 Cr, and the Total Assets amount to 2,582.11 Cr.

Who are the peers of the Aarti Pharma?

Aarti Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Strides Pharma, FDC, SPARC, Supriya Lifesci, and Innova Captab. Aarti Pharma has good management risk and capital structure, with a 1-year return of 58%, higher than SPARC but lower than Supriya Lifesci's 101.13%.

Peers: The peers of Aarti Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Strides Pharma, FDC, SPARC, Supriya Lifesci., and Innova Captab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Supriya Lifesci., while Good management risk is found at Divi's Lab., Torrent Pharma, and Aarti Pharma. Below Average management risk is noted at Strides Pharma and SPARC. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Aarti Pharma, FDC, Strides Pharma, and SPARC, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Aarti Pharma, FDC, and Supriya Lifesci., while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Strides Pharma and SPARC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 101.13%, while the lowest is SPARC at -7.40%. Aarti Pharma's 1-year return is 58.00%, which is significantly higher than SPARC's but lower than Supriya Lifesci.'s. Additionally, the peers with negative six-month returns are Strides Pharma and FDC.

Who are in the management team of Aarti Pharma?

As of March 2023, Aarti Pharma's management team includes Rashesh C Gogri (Chairman), Hetal Gogri Gala (Vice Chairperson & Managing Director), Narendra Jagannath Salvi (Managing Director), and several non-executive and independent directors. The team combines executive leadership with independent oversight for effective governance.

As of March 2023, the management team of Aarti Pharma includes the following members:<BR><BR>1. Rashesh C Gogri - Chairman<BR>2. Hetal Gogri Gala - Vice Chairperson & Managing Director<BR>3. Narendra Jagannath Salvi - Managing Director<BR>4. Rajendra V Gogri - Non-Executive & Non-Independent Director<BR>5. Parimal H Desai - Non-Executive Director<BR>6. Bhavesh R Vora - Independent Director<BR>7. Vinay Gopal Nayak - Independent Director<BR>8. Vilas G Gaikar - Independent Director<BR>9. Jeenal Savla - Independent Director<BR>10. Rupal Vora - Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, with several independent directors contributing to the governance of the company.

What does Aarti Pharma do?

Aarti Pharmalabs Ltd manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, and New Chemical Entities (NCE) in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of ₹5,638 Cr and a net profit of ₹883 Cr, with a market cap of ₹8,574 Cr.

Overview: <BR>Aarti Pharmalabs Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives, operating within the Pharmaceuticals & Biotechnology industry as a Mid Cap company.<BR><BR>History: <BR>Aarti Pharmalabs Ltd was incorporated as a Public Limited Company in 2019 and changed its name from Aarti Organics Limited to Aarti Pharmachem Limited on July 1, 2021. The most recent quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 5,638 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 883 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 8,574 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.37% <BR>Debt-Equity: 0.18 <BR>Return on Equity: 13.69% <BR>Price to Book: 4.31 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Is Aarti Pharma overvalued or undervalued?

As of November 10, 2025, Aarti Pharma is fairly valued with a PE ratio of 28.73, lower than some peers like Sun Pharma and Divi's Lab but higher than Cipla, and has shown mixed performance with recent declines against the Sensex but a positive year-to-date return of 10.59%.

As of 10 November 2025, Aarti Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics, with a PE ratio of 28.73, an EV to EBITDA of 16.31, and a PEG ratio of 5.64. These ratios suggest that while the company is not undervalued, it is also not overvalued compared to its peers.<BR><BR>In comparison to its industry peers, Aarti Pharma's PE ratio is lower than that of Sun Pharma, which stands at 35.15, and significantly lower than Divi's Lab at 71.55, both of which are considered expensive. However, it is higher than Cipla's attractive valuation with a PE of 22.45. The stock has underperformed against the Sensex over the past week and month, with returns of -11.37% and -8.71%, respectively, although it has outperformed on a year-to-date basis with a return of 10.59%. Overall, Aarti Pharma appears to be fairly valued in the current market context.

How has been the historical performance of Aarti Pharma?

Aarti Pharma has shown significant growth from March 2022 to March 2025, with net sales increasing from 1,199.94 Cr to 2,115.07 Cr, and profit after tax rising from 122.25 Cr to 272.40 Cr, indicating improved profitability and operational efficiency. Total assets and liabilities grew proportionally, while cash flow from operations improved from -43.00 Cr to 331.00 Cr.

Answer:<BR>The historical performance of Aarti Pharma shows significant growth in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Aarti Pharma's net sales increased from 1,199.94 Cr in March 2022 to 2,115.07 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 1,199.94 Cr in March 2022 to 2,115.07 Cr in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from 206.95 Cr in March 2022 to 474.48 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose from 155.38 Cr in March 2022 to 360.69 Cr in March 2025, while profit after tax increased from 122.25 Cr to 272.40 Cr in the same period, showcasing a consistent enhancement in profitability. The earnings per share (EPS) grew from 26.83 in March 2022 to 30.05 in March 2025, further highlighting the company's financial health. On the balance sheet, total assets increased from 2,039.90 Cr in March 2022 to 2,906.41 Cr in March 2025, with total liabilities also rising from 2,039.90 Cr to 2,906.41 Cr, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 331.00 Cr in March 2025, compared to a negative cash flow of 43.00 Cr in March 2022, reflecting better cash management and operational performance.

Is Aarti Pharma technically bullish or bearish?

As of December 3, 2025, the market trend is mildly bearish, influenced by bearish signals from the MACD and moving averages, despite some bullish momentum from the RSI and mixed signals from the Bollinger Bands and KST.

As of 3 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD indicating bearish momentum and the daily moving averages also reflecting a bearish trend. The weekly RSI shows bullish momentum, but this is countered by the overall bearish signals from the MACD and moving averages. The Bollinger Bands are mildly bearish on the weekly timeframe, while the KST indicates bullishness, creating mixed signals. Overall, the lack of a definitive trend in Dow Theory further supports a neutral outlook, but the prevailing indicators lean towards a mildly bearish stance.

When is the next results date for Aarti Pharmalabs Ltd?

The next results date for Aarti Pharmalabs Ltd is 09 February 2026.

The next results date for Aarti Pharmalabs Ltd is scheduled for 09 February 2026.

Are Aarti Pharmalabs Ltd latest results good or bad?

Aarti Pharmalabs Ltd's latest results show a 71.78% increase in net profit quarter-on-quarter, with improved operating margins, but a concerning 35.18% decline in net profit and 19.62% drop in sales year-on-year indicate ongoing revenue challenges. Investors should watch for future trends in revenue stabilization or growth.

Aarti Pharmalabs Ltd's latest results present a mixed picture. On one hand, the company achieved a consolidated net profit of ₹47.96 crores, which is a significant increase of 71.78% compared to the previous quarter. Additionally, the operating margin improved to 23.67%, showing strong margin recovery and operational efficiency.<BR><BR>However, the year-on-year performance raises concerns. The net profit is down 35.18% compared to the same quarter last year, and net sales have also declined by 19.62% year-on-year, indicating persistent revenue challenges. This decline in sales suggests that the company is facing headwinds in terms of demand and competitive positioning in the pharmaceutical intermediates market.<BR><BR>Overall, while the sequential improvement in profitability and margins is a positive sign, the ongoing revenue contraction is a significant concern. Investors should closely monitor future quarters to see if this trend of margin recovery can be sustained alongside a stabilization or growth in revenue.

Has Aarti Pharmalabs Ltd declared dividend?

Yes, Aarti Pharmalabs Ltd has declared a dividend of 30% (₹2.5 per share) with an ex-date of February 16, 2026. The company has shown varying total returns, with significant growth over the 2 and 3-year periods, but recent shorter-term returns have been negative.

Aarti Pharmalabs Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 2.5<BR>- Ex-date: 16 Feb 26<BR><BR>Dividend Yield: 0.65%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -2.21%, the dividend return was 0.20%, resulting in a total return of -2.01%.<BR><BR>Over the past 6 months, the price return was -12.14%, the dividend return was 0.51%, leading to a total return of -11.63%.<BR><BR>In the 1-year period, the price return was 4.6%, the dividend return was 0.51%, culminating in a total return of 5.11%.<BR><BR>For the 2-year period, the price return was 47.46%, the dividend return was 1.43%, resulting in a total return of 48.89%.<BR><BR>In the last 3 years, the price return was 141.49%, the dividend return was 3.06%, leading to a total return of 144.55%.<BR><BR>Over the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, Aarti Pharmalabs Ltd has declared a dividend and has shown varying total returns over different periods, with significant growth in the 2 and 3-year periods, while recent returns over shorter periods have been negative.

Should I buy, sell or hold Aarti Pharmalabs Ltd?

Why is Aarti Pharmalabs Ltd falling/rising?

As of 16-Mar, Aarti Pharmalabs Ltd's stock price is Rs 628.45, down -3.43%, with significant declines over various time frames and negative earnings reports. The company's poor financial performance and low mutual fund interest contribute to a bearish outlook.

As of 16-Mar, Aarti Pharmalabs Ltd is experiencing a decline in its stock price, currently at Rs 628.45, reflecting a change of -22.35 (-3.43%). The stock has been underperforming significantly, having lost -8.33% over the last four days, and is trading lower than its moving averages across various time frames, indicating a bearish trend. <BR><BR>In the past week, the stock has decreased by -7.78%, while the benchmark Sensex has only fallen by -2.66%. Over the past month, Aarti Pharmalabs has seen a decline of -11.72%, compared to a -9.34% drop in the Sensex. Year-to-date, the stock is down -16.46%, which is worse than the Sensex's decline of -11.40%. <BR><BR>The company's financial performance has also been troubling, with a reported fall in earnings per share (EPS) of -19.99% and negative results declared for the last three consecutive quarters. Additionally, the company's net sales have decreased at an annual rate of -2.13% over the last five years, contributing to a perception of poor long-term growth potential. <BR><BR>Despite a low Debt to EBITDA ratio of 1.03, which indicates a strong ability to service debt, the overall sentiment remains negative due to the significant drop in profits by -13.4% over the past year. Furthermore, domestic mutual funds hold only a small stake of 1.92% in the company, suggesting a lack of confidence in its current valuation or business prospects. <BR><BR>Overall, the combination of declining stock performance, negative earnings reports, and poor growth metrics has led to the current downward trend in Aarti Pharmalabs Ltd's stock price.

Which are the latest news on Aarti Pharma?